Request Demo

Last update 29 Aug 2026

Lixisenatide

Last update 29 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide, DesPro38Exendin-4(1-39)-Lys6-NH2, Lixisenatide (JAN/USAN/INN)

+ [13]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication

Acute Coronary SyndromeDiabetes Mellitus, Type 1Gastroparesis+ [2]

Originator Organization

Zealand Pharma A/S

Active Organization

Sanofi-Aventis Canada, Inc.

Sanofi-Aventis U.S. LLCSanofi KK

Inactive Organization

Sanofi

Sanofi Winthrop Industrie SASanofi-Aventis Recherche & Développement SA

+ [2]

License Organization

Sanofi

Royalty Pharma Plc

Zealand Pharma A/S

Drug Highest PhaseApproved

First Approval Date

European Union (31 Jan 2013),

Diabetes Mellitus, Type 2

Regulation-

Structure/Sequence

Sequence Code 25682

Source: *****

Clinical Trials associated with Lixisenatide

NCT07173712

/ Not yet recruitingPhase 4IIT

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Hypoglycemic Agents: A Multicenter, Open-Label, Randomized Controlled Study

Failure of oral antidiabetic drugs (OADs) is a frequent challenge in patients with type 2 diabetes mellitus (T2DM), and inadequate long-term glycemic control substantially increases the risk of diabetic complications. Short-term intensive insulin therapy (SIIT) is an established approach to mitigate glucotoxicity; however, the optimal strategy to sustain long-term glycemic benefits after SIIT in T2DM patients with OAD failure remains unclear. To address this gap, we designed a randomized controlled trial to evaluate subsequent treatment options, aiming to identify a simple and effective regimen for patients with poor glycemic control who undergo SIIT.
A total of 324 eligible patients will be enrolled. After screening, previous antidiabetic regimens will be discontinued, and patients will be randomly assigned to the SIIT- iGlarLixi group (A), the SIIT-IDegAsp group (B), or the SIIT-iGlar group (C). All patients will be hospitalized for short-term insulin pump therapy, followed by 24 weeks of treatment: group A with insulin glargine/lixisenatide, group B with insulin degludec/aspart, and group C with insulin glargine U300 plus metformin. During the extension follow-up period, patients in all groups may either continue their assigned regimen or return to their original pre-study therapy. A total of 10 clinic visits are scheduled for each patient throughout the study.
Primary endpoint is proportion of patients achieving glycosylated hemoglobin A1C <7% at 24 weeks.Secondary endpoints include proportion of patients achieving glycosylated hemoglobin A1C <6.5% at 24 weeks; differences in weight gain, hypoglycemic events among treatment groups, and differences in proportion of patients continuing the assigned regimen, glycemic control and body weight at the extension follow-up period.

Start Date15 Mar 2026

Sponsor / Collaborator

Sun Yat-Sen University

NCT07117240

/ Enrolling by invitationPhase 4IIT

Efficacy of Treatment Strategies for Steroid-induced Diabetes - a Comparison of GLP-1 Receptor Agonist Plus Basal Insulin With Intensive Insulin Therapy

Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects. In the proposed research, the aim is to assess the metabolic efficacy and safety of fixed-ratio combination therapy (basal insulin + GLP-1 receptor agonist) compared to standard insulin therapy in patients with SID. In a selected group of patients, a randomised clinical trial would be conducted to assess the potential benefits of GLP-1 receptor agonists in the management of SID.

Start Date10 Jul 2025

Sponsor / Collaborator

Warszawski Uniwersytet Medyczny

CTRI/2024/10/075222

/ Active, not recruitingPhase 4

A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India

Start Date28 Oct 2024

Sponsor / Collaborator

Sanofi Healthcare India Pvt Ltd.

100 Clinical Results associated with Lixisenatide

100 Translational Medicine associated with Lixisenatide

100 Patents (Medical) associated with Lixisenatide

562

Literatures (Medical) associated with Lixisenatide

01 Sep 2026·PHARMACOLOGICAL RESEARCH

GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles

Article

Author: Qin, Muting ; Li, Yao ; Tuersun, Adili ; Chen, Huanxue ; Fan, Xichen ; Xing, Haoyue ; Zhao, Xin ; Abuduaini, Subinuer ; Xu, Xiaoou

IMPORTANCE:

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in adolescents with overweight or obesity, but their comparative effects on cardiometabolic outcomes across different agents remain uncertain. We aimed to compare the efficacy and safety of different GLP-1RAs on key cardiometabolic parameters in adolescents with overweight or obesity, with or without type 2 diabetes.

METHODS:

We searched PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov from inception to May 1, 2026. Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included. Two reviewers independently extracted data and assessed risk of bias following PRISMA guidelines for network meta-analysis. We used a Bayesian random-effects model for data synthesis.

RESULTS:

17 RCTs with 1230 participants were included. Semaglutide 2.4 mg SC was associated with the largest reductions in body weight (mean difference -18.00 kg; 95% credible interval -24.34 to -11.69, high confidence), BMI (-5.9 kg/m², -10.5 to -1.3, high confidence), and waist circumference (-12.2 cm, -21.67 to -2.67). For glycaemic control, dulaglutide 1.5 mg SC showed the largest reduction in HbA1c (-1.50%, -1.84 to -1.15, high confidence), and lixisenatide 20 ug SC showed the largest reduction in fasting plasma glucose (-3.98 mmol/L, -7.46 to -0.60); however, these rankings derive from networks with sparse head-to-head evidence and wide credible intervals for indirect comparisons. Exenatide 20 ug SC was associated with a reduction in systolic blood pressure (-6.64 mmHg, -13.22 to -0.17) based on limited indirect evidence from early-phase trials. No agent improved lipid profiles in a statistically significant manner.

CONCLUSION:

In this network meta-analysis of adolescents with overweight or obesity, GLP-1RAs showed differential cardiometabolic profiles. Semaglutide 2.4 mg produced the largest point estimates for weight-related outcomes, dulaglutide 1.5 mg and lixisenatide 20 ug for glycaemic endpoints, and exenatide 20 ug for systolic blood pressure. These findings are hypothesis-generating: most active-treatment comparisons were indirect, many nodes were informed by single trials, and SUCRA rankings should not be interpreted as evidence of definitive clinical superiority.

01 Aug 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy

Article

Author: Dani, Sourbha S ; Verma, Anushka ; Ganatra, Sarju ; Patel, Tirth ; Panchal, Krisha ; Ramsey, Kathryn Moynihan ; Patel, Vahin ; Upadhyay, Jagriti ; Shah, Jui ; Makwana, Bhargav ; Ramsey, David J ; Kong, Yixin ; Khadke, Sumanth ; Vivekanandan, Suja

PURPOSE:

To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials.

DESIGN:

Retrospective, population-based cohort study.

PARTICIPANTS:

Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022.

METHODS:

The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least 2 prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least 6 months apart.

MAIN OUTCOME MEASURES:

Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a 2-year follow-up period.

RESULTS:

After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44).

CONCLUSIONS:

In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.

01 Aug 2026·Epilepsy Currents

The Effect of GLP-1 Receptor Agonists on Epilepsy: No Appetite for Seizures

Article

Author: Karakis, Ioannis

Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes Cheng CY, Lo SC, Huang CN, Yang YS, Wang YH, Kornelius E. Neurology . 2026;106(1):e214509. doi:10.1212/WNL.0000000000214509. Epub 2025 Dec 10. PMID: 41370744. Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), real-world comparative effectiveness data remain limited. We aimed to evaluate whether GLP-1 RA use is associated with a lower risk of incident epilepsy compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use in adults with T2DM. Methods: We conducted a retrospective cohort study using the TriNetX network from 2015 to 2023, including adults aged 18 years or older with T2DM who were new users of either GLP-1 RAs or DPP-4is. Patients with a previous diagnosis of epilepsy or seizure, or those using antiepileptic drugs, were excluded. The primary outcome was incident epilepsy, identified using ICD-10-CM codes. Propensity score matching (1:1) was performed based on demographics, socioeconomic status, body mass index, comorbidities, and baseline medications. Cox proportional hazard models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). We also conducted prespecified subgroup and sensitivity analyses to assess the robustness of the findings. Results: After matching, 452 766 patients were included (226 383 in each group; mean age 60.5 years; 47.1% female). During follow-up, 1670 individuals in the GLP-1 RA group and 1886 in the DPP-4i group developed epilepsy, corresponding to cumulative incidences of 2.35% versus 2.41%. Glucagon-like peptide-1 receptor agonists use was associated with a significantly lower risk of epilepsy (HR 0.84, 95% CI 0.78-0.90), with protective associations evident at 1 year (HR 0.71, 95% CI 0.62-0.80), 3 years (HR 0.81, 95% CI 0.74-0.88), and 5 years (HR 0.82, 95% CI 0.76-0.88). Among individual agents, semaglutide showed the strongest association (HR 0.68, 95% CI 0.60-0.77). The results were consistent across major subgroups, including both age and sex. Sensitivity analyses excluding patients with overlapping or switching exposure yielded similar findings (HR 0.71, 95% CI 0.64-0.78). Discussion: Glucagon-like peptide-1 receptor agonists therapy was associated with a significantly lower epilepsy risk compared with DPP-4i use in adults with T2DM. These results support the hypothesis that GLP-1 RAs may exert neurologic benefits beyond glycemic control. Limitations include the observational design and potential residual confounding.Seizure Recurrence after GLP-1 Receptor Agonist Initiation in Adults with Epilepsy AbuAlrob MA, Hussein A, Abdellatif R, Itbaisha A, Zammar K, Mesraoua B. Epilepsia . 2025. doi:10.1111/epi.70022. Epub ahead of print. PMID: 41251033. Objective: To examine whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods: We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Research Network (January 2003-August 2025), including adults ≥18 years with ≥3 epilepsy or recurrent seizure diagnoses. Patients initiating a GLP-1 RA (exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, or tirzepatide) without prior comparator therapy were compared with those initiating other glucose-lowering agents (sodium–glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, sulfonylureas, or insulin) without GLP-1 RA exposure. Propensity score matching (1:1) was performed on 82 covariates, yielding 8688 matched pairs. Outcomes were assessed using Cox proportional hazards models. Results: After matching, the mean age was 52.6 years, and 67.6% were female. Median follow-up was 514 days (interquartile range [IQR] 671) for GLP-1 RA initiators and 415 days (IQR 769) for comparators. Glucagon-like peptide-1 receptor agonists initiation was associated with lower risk of seizure recurrence (HR 0.82, 95% confidence interval [CI] 0.78-0.86; RD −2.1%), hospitalization (HR 0.35, 95% CI 0.29-0.43; RD −2.6%), and all-cause mortality (HR 0.40, 95% CI 0.34-0.47; RD −4.8%). Associations with status epilepticus (HR 0.75, 95% CI 0.66-0.85; RD −0.7%) and ICU admission (HR 0.82, 95% CI 0.69-0.96; RD −0.3%) were smaller; the latter was not statistically significant. Significance: In this large multinational cohort, GLP-1 RA initiation was associated with reduced risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies. These hypothesis-generating findings warrant confirmation in prospective studies before translation into clinical practice.

News (Medical) associated with Lixisenatide

13 Aug 2026

·www.fiercebiotech.com

Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision

As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million. Takeda and Protagonist are expecting a decision from the FDA in the third quarter, based on a phase 3 trial that linked the peptide hepcidin mimetic to a 76.9% response rate in patients with polycythemia vera (PV). Rusfertide mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and red blood cell production. Protagonist has previously touted the drug as a way for PV patients to reduce or even eliminate the need for regular phlebotomy. Takeda paid Protagonist $300 million upfront for rights to the drug candidate in 2024, but Zealand’s history with rusfertide stretches back to 2012, when the Danish biopharma entered a research collaboration with Protagonist to develop disulfide-rich peptides (DRPs). That agreement gave Zealand responsibility for clinical development of any resulting DRPs discovered under the collaboration. The partnership was terminated in 2014, but Zealand retained an economic interest in what would become rusfertide. Now, Copenhagen-based Zealand has agreed to sell its economic interests in the drug to Royalty Pharma for a total of $100 million. This payout will consist of $50 million upfront, with the remaining $50 million due a year later. Even after the deal, Zealand will still be entitled to 0.25% royalties on net global sales of rusfertide above $1.5 billion. For its part, Royalty will gain 0.75% royalties on sales above the same point. Zealand, which described rusfertide as a “non-core asset,” had 14.4 billion Danish kroner ($2.2 billion) in the bank at the end of June. The company said the fresh cash could help fund its strategy to launch five products by 2030. These include obesity plays like the amylin analog petrelintide, which is set to enter phase 3 trials in the coming months, and the Boehringer Ingelheim-partnered glucagon/GLP-1 agonist survodutide, which is already in late-stage development. “This agreement converts a future potential royalty stream into immediate capital that will be redeployed against future growth opportunities in line with our key strategic priorities under our Metabolic Frontier 2030 strategy,” Zealand’s Chief Financial Officer Henriette Wennicke said in an August 12 release. As the world’s largest buyer of biopharma royalties, the agreement with Zealand follows a string of deals this year that has seen Royalty secure a stake in Neurimmune’s AstraZeneca-partnered transthyretin-mediated amyloidosis drug, co-fund Johnson & Johnson’s chronic autoimmune disease asset and support Teva’s vitiligo therapy . Royalty’s relationship with Zealand stretches back to 2018 , when the firm bought a slice of the rights to two diabetes drugs, Soliqua and Adlyxin, which were both developed at Zealand before being licensed to Sanofi. “We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health,” Royalty CEO Pablo Legorreta said. “This transaction underscores Royalty Pharma’s role as a long-term, trusted partner to biopharma companies as they advance important medicines,” Legorreta added in the release. “Furthermore, we believe rusfertide has the potential to become a transformative treatment option for patients with polycythemia vera, and we look forward to its continued progress through regulatory review.”

28 May 2026

·www.businesswire.com

Ontada Study Presented at ASCO 2026 Examines Real-World Use of GLP‑1 Receptor Agonists and Survival Outcomes Across Common Cancers in U.S. Community Oncology

BOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present a real-world observational research study in an oral presentation at the American Society of Oncology (ASCO) Annual Meeting examining GLP-1 receptor agonist (RA) utilization and overall survival outcomes among patients treated in U.S. community oncology practices. The study, titled, “GLP 1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort,” analyzed patients diagnosed with cancer between January 2021 and October 2024, with follow-up through October 2025. Investigators identified 418 patients treated with a GLP-1 receptor agonist and 3,476 non-users, with matching by cancer type and diagnosis year to evaluate overall survival (OS) outcomes. Key Data Findings Propensity-score adjusted Cox proportional hazards models evaluated the association between GLP1 RA use and overall survival among patients diagnosed with breast, prostate, colorectal, lung, hepatocellular or renal cancer. After adjustment for confounders including age, BMI, cancer stage and type, GLP‑1 receptor agonist use was significantly associated with improved overall survival (hazard ratio 0.66; 95% CI 0.45–0.97; p = 0.0031). “While GLP-1 therapies are well established for metabolic disease, emerging preclinical and observational data suggest potential anticancer effects, yet large-scale studies investigating this association have been limited,” said Jess Paulus, ScD, vice president of Real-World Research at Ontada and presenting author of the study. “As use of these therapies continues to expand, high-quality real-world data are essential to understanding their broader impact. Our findings demonstrate the value of real-world evidence in identifying anticancer signals and helping efficiently guide future research and prioritization of prospective studies.” Study Methodology This retrospective analysis used data collected between January 2021 and October 2024, with follow‑up through October 2025, and evaluated GLP‑1 receptor agonist use, including dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Overall survival was measured from initial cancer diagnosis to death from any cause, with methods applied to address immortal time bias. Among patients who received a GLP‑1 receptor agonist, median age was 63 years, 58% were White, and 57% had a body mass index (BMI) ≥30 kg/m². Semaglutide accounted for the majority of prescriptions (55%). By comparison, non‑users had a median age of 68 years, 58% were White, and 28% had BMI ≥30 kg/m². Most GLP‑1 users (74%) initiated therapy after initial cancer diagnosis, of whom 7% initiated after a metastatic diagnosis, with breast (27%) and prostate (13%) cancers representing the most common malignancies among this group. “At Ontada, our focus is on advancing cancer care by transforming real-world data into meaningful insights,” said Christine Davis, president, Ontada. “This research reflects Ontada’s commitment to generating high-quality, real-world evidence that helps advance how cancer is understood and treated. By studying emerging therapies within community oncology settings, we can help surface insights that inform future research and ultimately support better outcomes for patients.” Other Research & Activities at ASCO 2026 Ontada is a part of McKesson, which has a broad portfolio of oncology and multispecialty solutions and partners that provide research, insights, technologies and services that help to address barriers and improve cancer and multispecialty care. At ASCO, McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 171 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies and early-phase studies. For a comprehensive list of Ontada’s 14 accepted abstracts, visit Ontada’s ASCO 2026 site. Additionally, visit the Ontada Booth (#30123) at the McCormick Place Convention Center from May 29 – June 2 to explore the data presented at ASCO and discuss Ontada’s solutions. Expert Panel on Community Oncology During ASCO 2026 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 3, 2026, at 12 p.m. ET, titled, “Delivering Excellence, Close to Home.” Panelists include Jason Hammonds, president of Oncology & Multispecialty for McKesson, John Schuler MD, medical director and radiation oncologist with Compass Oncology, and Dr. Patt. Register and join the panelists as they share their insights and perspectives on what is working today—and what needs to evolve—to support and strengthen community oncology as a foundational component of the cancer care ecosystem. About Ontada® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the belief that precise insights—delivered exactly at the point of need—can save more patients’ lives. Ontada connects the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by leading life sciences companies. For more information, visit ontada.com. About McKesson Oncology & Multispecialty Our Oncology & Multispecialty segment delivers a portfolio of integrated solutions that support patient care by accelerating drug development, expanding access to high-quality care close to home and ensuring life-saving therapies reach the patients who need them most. We provide practice management, technology solutions, specialty drug distribution, clinical trial and group purchasing services, along with pharmacy solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology. We partner behind the scenes with healthcare providers in local communities, supporting their operations so that they can stay focused on who matters most – patients.

02 Mar 2026

·www.prnewswire.com

GLP-1 drugs associated with reduced need for emergency care for migraine

Drugs also related to lower use of drugs to stop, prevent attacks Highlights: For people with chronic migraine, starting GLP-1 drugs for conditions like diabetes may be associated with fewer emergency department visits. A preliminary study has found that people who started GLP-1 drugs were approximately 10% less likely than those who started topiramate to visit the emergency department over the following year. They were also about 14% less likely to be hospitalized for any reason during the year. This observational study does not prove that the drugs lower the need for emergency care for people with migraine. It only shows an association. MINNEAPOLIS, March 2, 2026 /PRNewswire/ -- For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online. The people with chronic migraine starting GLP-1 drugs were compared to people with chronic migraine who were starting topiramate, a drug commonly used to prevent migraine. The study does not prove that GLP-1 drugs lower the need for emergency care and additional drugs for migraine; it only shows an association. "People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them," said study author Vitoria Acar, MD, of the University of Sao Paulo in Brazil. "Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet. " For the study, researchers analyzed a health-record database of people who had a chronic migraine diagnosis based on medical records. Chronic migraine is defined by having a headache on 15 or more days per month for at least three months, where at least eight of those days include typical migraine symptoms like throbbing pain, nausea, or light sensitivity. People who had started taking GLP-1 drugs for another condition within a year of a recorded diagnosis of chronic migraine were compared to people who started taking topiramate during that same period. The two groups were matched for factors such as age, body mass index, other health conditions, and prior migraine treatments. There were about 11,000 people in each group. The GLP-1 drugs studied included liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide and albiglutide. The researchers used medical records to track what happened to both groups over the following year. This included overall emergency department visits, hospitalizations, nerve block procedures, and any new prescriptions for medications used to stop or prevent migraine attacks. After accounting for differences in age, body weight, other health conditions, and prior migraine treatments, researchers found that 23.7% of people starting GLP-1 drugs visited the emergency department over the following year, compared with 26.4% of those starting topiramate. People starting GLP-1 drugs were about 10% less likely to have an emergency department visit, 14% less likely to be hospitalized, and about 13% less likely to undergo a nerve block procedure or receive a triptan prescription compared with those taking topiramate. They were also less likely to be prescribed new preventive migraine medications. Compared with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called gepants. There was no statistically significant difference between the two groups in the proportion of people starting beta blockers. "Chronic migraine often overlaps with metabolic and inflammatory conditions such as obesity, insulin resistance, sleep apnea and depression, which can make treatment more difficult," Acar said. "Early research is looking at whether GLP-1 drugs' anti-inflammatory and neurovascular effects could play a role in migraine treatment, not just through weight loss." Because this was an observational study, it cannot prove that GLP-1 drugs caused the lower need for emergency care or additional medications. Even though the groups were matched at the start, researchers could not measure things that changed over the year, such as weight loss, migraine severity, medication use patterns or lifestyle changes. These unmeasured factors could also have played a role. Further studies are needed. The study was supported by patient philanthropy and Miles for Migraine. Discover more about migraine at Brain & Life®, from the American Academy of Neurology. This resource also offers a website, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world's leading experts in brain health. Follow Brain & Life® on Facebook, X, and Instagram. The American Academy of Neurology is the leading voice in brain health. As the world's largest association of neurologists and neuroscience professionals with more than 44,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN's mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine. Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube. SOURCE American Academy of Neurology 21% more press release views with Request a Demo

Clinical Result

100 Deals associated with Lixisenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D09729	Lixisenatide	A10BJ03	DB09265

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	European Union	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Iceland	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Liechtenstein	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Norway	Sanofi Winthrop Industrie SA	31 Jan 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 3	United States	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	China	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Japan	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Argentina	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Australia	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Austria	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Belarus	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Belgium	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Brazil	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Bulgaria	Sanofi	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	oqtmokrxis(skcswzbbsv) = tzhemcpugj xdefuswmrl (monknxpysl )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	oqtmokrxis(skcswzbbsv) = xcfomzlkpl xdefuswmrl (monknxpysl )
NCT03439943 (LIXIPARK, Pubmed \| N Engl J Med)	Phase 2	Parkinson Disease	156	Lixisenatide	zakdtgbsbr(inajczsnrh) = Nausea occurred in 46% of participants receiving lixisenatide meaqyhsphk (uiyrledsaj ) View more	Positive	04 Apr 2024
				Placebo
NCT03439943 (LIXIPARK, Literature) Manual	Phase 2	Parkinson Disease	156	Lixisenatide	ojwoqgibyr(jbkkdijyjx) = wbayklyrsp jtlnzjbhwx (xqsdjomrnk ) View more	Positive	03 Apr 2024
				Placebo	ojwoqgibyr(jbkkdijyjx) = luvwwdacnm jtlnzjbhwx (xqsdjomrnk ) View more
NCT03798054 \| NCT03798080 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	-	iGlarLixi	rxfmvjihqh(dhxkjahbho): P-Value = 11.45	-	30 Mar 2023
				Glargine 100 U/mL
NCT03798080 (LixiLan-L-CN, Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	426	iGlarLixi	apirnozxkj(wcejttiqko) = ztysjnctqm myardsvivj (qynnkypeyw ) View more	Superior	28 Jun 2022
				insulin glargine	apirnozxkj(wcejttiqko) = rywkkhhnjn myardsvivj (qynnkypeyw ) View more
STAR.Ro (Pubmed) Manual	Not Applicable	Diabetes Mellitus, Type 2	901	Lixisenatide+Insulin glargine	dolbokswrp(rkfcikjcpb) = ivoxucwgdz upamhvrtfd (gdnpjlnphi, -1.4 to -1.2) View more	Positive	27 May 2022
NCT03798054 (LixiLan-O-AP, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	878	iGlarLixi	fcxjhcahbd(mttoxwtqtx) = jfgdflmejz podaxvskyn (atfapttnys ) View more	Positive	19 Apr 2022
				Insulin glargine 100 U/mL	fcxjhcahbd(mttoxwtqtx) = rwbcmsvwrz podaxvskyn (atfapttnys )
NCT02231658 (EASD2020)	Phase 1	Diabetes Mellitus, Type 2	57	Lixisenatide	joyarqgtyg(xfcapcaiek) = vesahbozsy ehilczulwt (ddhdlzspyg ) View more	Positive	24 Sep 2020
				Liraglutide	joyarqgtyg(xfcapcaiek) = xlcygidexv ehilczulwt (ddhdlzspyg )
NCT02231658 (Pubmed \| Diabetes Care)	Phase 1	Diabetes Mellitus, Type 2	57	Lixisenatide	fwvntjcivy(kjkcyovvgw) = jpbxqvzgyw medttpkqbn (tqlusawrjt, -40.6, - 0.8) View more	-	09 Jul 2020
				Liraglutide	lvggdffwaj(wqqtdebacs) = zvfhhpkdtz afwpkxwrou (ukjdeeykbv, 3 - 46)
NCT02640118 (Pubmed \| Diabetologia)	Not Applicable	Diabetes Mellitus	12	Lixisenatide	mqwgfseeap(dmgkaifzod) = xugbgqktwe yczxdknocr (rxcqeoroqb ) View more	-	01 Jul 2020
				Placebo	mqwgfseeap(dmgkaifzod) = glbasgeewj yczxdknocr (rxcqeoroqb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis